Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJing Sui

Discussion

Loading...

Member takes

Overview

Single-center analysis reveals high response rates for glofitamab in relapsed/refractory B-cell lymphoma, indicating feasible chemotherapy combinations.

Key Points

  • Overall response rate was 92.8%, with complete response observed in 35.7% of patients treated with glofitamab.
  • 15 of 20 patients presented with Cytokine release syndrome (grade ≥1), while lymphopenia affected 12 patients post-treatment.
  • Retrospective review of glofitamab efficacy in Chinese patients with relapsed/refractory B-cell lymphoma explored multiple treatment regimens.
  • Glofitamab therapy potentially offers superior outcomes in this population with manageable adverse events.

Cite This Study

Jing Sui (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e284https://doi.org/10.1182/blood-2025-7204
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study2025
  2. 2Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  3. 3Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  4. 4Efficacy, safety, and T-cell population dynamics of glofitamab monotherapy in relapsed/refractory B-cell lymphoma2025
  5. 5Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025